Announcing FutureTox III -- November 19-20 in Arlington, Virginia

FutureTox III:

Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making

 

FutureTox III: Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making will be held November 19–20, 2015, at the Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia. This conference was developed by the Scientific Liaison Coalition (SLC) and associated stakeholders and follows the well-received FutureTox II Contemporary Concepts in Toxicology conference also initiated by the SLC.  The Teratology Society is a member of the SLC and a supporter of FutureTox III.

FutureTox III will focus on building the high throughput risk assessment paradigm, taking the science of in vitro data and in silico models forward. Thus, the conference will explore the central question: What progress is being made to address challenges in applying and implementing the emerging “big data” toolbox for risk assessment and regulatory decision-making?

Automated high-throughput screening (HTS) and high-content screening (HCS) of large chemical inventories, together with newer complex culture models utilizing human cells, microtissue systems, and integrative models, are now providing vast amounts of data that can be used to inform regulatory toxicity testing. These methods, together with novel approaches to model exposure and kinetics, creates an opportunity for a paradigm shift toward diversified and high-throughput risk assessment (HTRA) approaches for regulatory decision-making. Overall, the approach results in more rapid, more relevant, and more nimble discovery-screening and prioritization efforts with less reliance on animal testing. The time is right to discuss and debate how TT21C science, approaches, and technologies will be applied in risk assessment and regulatory decision-making.

The overarching objectives of the meeting are toward:

  • Advancing the cornerstones for high-throughput risk assessment through exploration and discussions with multiple stakeholders

  • Taking TT21C in vitro and in silico models forward while reducing reliance on animal testing

  • Exploring progress and identifying challenges in implementing the emerging “big-data” toolbox for risk assessment and regulatory decision-making.

The conference will include plenary sessions by invited speakers, topical breakout groups, and a poster reception , for which abstracts may be submitted starting in early June and ending August 15. Junior and senior scientists are encouraged to share their research

For more information and to register, please visit the FutureTox III website.

 

Recent Stories
Announcing the New Teratology Society Innovator Award

FDA Launches Predictive Toxicology Roadmap

PODCAST: Secrets of the Human Brain Revealed: Development, Disease & the Zika Virus